MedPath

A Study to Compare the Effectiveness of Different Anti-HIV Drug Regimens in Keeping Levels of HIV in the Blood as Low as Possible

Phase 2
Completed
Conditions
HIV Infections
Registration Number
NCT00000939
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Brief Summary

This study will look at different anti-HIV drug regimens to see which works best to keep the level of HIV (viral load) in the blood as low as possible during maintenance therapy. You will be assigned randomly (like tossing a coin) to 1 of 3 groups:

Group 1: Didanosine plus stavudine plus hydroxyurea (ddI/d4T/HU). Group 2: Didanosine plus stavudine plus efavirenz (ddI/d4T/EFV). Group 3: This group of patients will remain on their current drug regimens. This study will last approximately 3 years; you will receive study medications for the duration of the study.

Anti-HIV drug regimens that include protease inhibitors (PIs) are very good at lowering viral load. However, some patients have a rise in HIV levels while on PI maintenance. It may be possible to keep HIV levels low using another class of drugs for maintenance that are easier to take and less expensive than PIs. If viral load increases while a patient is taking this second group of drugs, it may be possible to restart the PI drug regimen and again decrease HIV levels.

Detailed Description

Combination antiretroviral therapies using protease inhibitors (PIs) are capable of suppressing plasma HIV RNA to undetectable levels. However, approximately 10% of patients who achieve undetectable viral loads will experience a detectable rise in HIV RNA each year. When HIV replication has been suppressed to very low levels, it may be possible to consolidate antiretroviral therapy into a simpler and potentially less toxic "maintenance" regimen without a PI. Such a regimen would ideally be potent enough to continue to maintain viral suppression but use agents that are better tolerated, more easily salvaged, less expensive, and/or more convenient than PI-containing regimens. Subsequent rises in HIV viremia with non-PI maintenance regimens may respond to resumption of the pre-maintenance PI-containing regimen, extending the use of the potent PI class.

Patients are randomized 1:1:1 to treatment with ddI/d4T/HU (Arm A) versus ddI/d4T/EFV (Arm B) versus continuation of the pre-entry PI-containing regimen (Arm C). Viral load is measured at Weeks 1, 2, 4, 8, 12, 16, 20, and 24, then every 8 weeks for up to 3 years. Upon virologic failure (plasma HIV RNA greater than or equal to 200 copies/ml), or drug intolerance, patients on the maintenance regimens (Arms A and B) restart their pre-entry PI-containing regimen. Patients on Arm C are managed according to best medical judgment of their primary care provider in the event of virologic failure.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
150
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (19)

Santa Clara Valley Med Ctr / AIDS Community Rsch Consortium

🇺🇸

San Jose, California, United States

San Mateo AIDS Program / Stanford Univ

🇺🇸

Stanford, California, United States

Bellevue Hosp / New York Univ Med Ctr

🇺🇸

New York, New York, United States

Cornell Univ Med Ctr

🇺🇸

New York, New York, United States

Ohio State Univ Hosp Clinic

🇺🇸

Columbus, Ohio, United States

Univ of Cincinnati

🇺🇸

Cincinnati, Ohio, United States

Indiana Univ Hosp

🇺🇸

Indianapolis, Indiana, United States

Willow Clinic

🇺🇸

Menlo Park, California, United States

Univ of Miami School of Medicine

🇺🇸

Miami, Florida, United States

Division of Inf Diseases/ Indiana Univ Hosp

🇺🇸

Indianapolis, Indiana, United States

Stanford Univ Med Ctr

🇺🇸

Stanford, California, United States

Beth Israel Med Ctr

🇺🇸

New York, New York, United States

Chelsea Ctr

🇺🇸

New York, New York, United States

Harvard (Massachusetts Gen Hosp)

🇺🇸

Boston, Massachusetts, United States

Methodist Hosp of Indiana / Life Care Clinic

🇺🇸

Indianapolis, Indiana, United States

Univ of Pennsylvania at Philadelphia

🇺🇸

Philadelphia, Pennsylvania, United States

Univ of Rochester Medical Center

🇺🇸

Rochester, New York, United States

Univ of North Carolina

🇺🇸

Chapel Hill, North Carolina, United States

Beth Israel Deaconess - West Campus

🇺🇸

Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath